Opendata, web and dolomites

ENDOCAM SIGNED

TARGETING ENDOTHELIAL CELL AND CANCER AMOEBOID MOVEMENT TO OVERCOME RESISTANCE TO ANTI-VEGF AND ANTI-PROTEASE THERAPIES

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ENDOCAM project word cloud

Explore the words cloud of the ENDOCAM project. It provides you a very rough idea of what is the project "ENDOCAM" about.

followed    unlike    migration    motility    synthetic    angiogenesis    vascular    body    mechanisms    disease    cysteine    movement    progression    strategies    vegf    candidates    ephrin    movements    molecules    adaptations    expectations    cell    mpi    indifference    physiological    showed    glide    treatment    resistance    ecm    degrade    ascribed    therapeutic    vegfa    vessel    time    impairing    attack    cells    metallo    amoeboid    progress    cargo    overcoming    regulation    serine    progenitor    preliminary    mixture    shared    mimicking    mpis    barriers    opportunistic    receptors    cytoskeleton    give    mature    physiologic    metalloproteinase    therapy    patients    differences    ecs    connection    disregarded    existence    onset    invasion    multiple    anti    epcs    mesenchymal    blood    environment    skip    stimulation    proteases    liposomes    perspective    protease    endothelial    inhibitors    clinical    humans    outcomes    actin    containing    strategy    cancer    experiments    tumors    hypothesized    cortical   

Project "ENDOCAM" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI FIRENZE 

Organization address
address: Piazza San Marco 4
city: Florence
postcode: 50121
website: http://www.unifi.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.unifi.it
 Total cost 244˙269 €
 EC max contribution 244˙269 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2020-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI FIRENZE IT (Florence) coordinator 244˙269.00
2    THE REGENTS OF THE UNIVERSITY OF CALIFORNIA US (OAKLAND CA) partner 0.00

Map

 Project objective

Unlike mesenchymal migration, the amoeboid motility doesn’t require proteases and is an opportunistic movement of cancer cells which allows cells to glide through, rather than degrade, ECM barriers, using movements based on adaptations of the cell body. Preliminary experiments we conducted using a mixture of physiologic inhibitors of serine-proteases, metallo-proteases and cysteine-proteases, thus mimicking a physiological environment, showed no differences in vessel formation for both Endothelial Progenitor Cells (EPCs) and mature Endothelial Cells (ECs) under mesenchymal or amoeboid conditions. Thus, we hypothesized the existence of an “amoeboid angiogenesis”. We also hypothesized that the failure of cancer treatment using synthetic metalloproteinase inhibitors (MPIs) could be ascribed to the ability of cancer and ECs to skip the attack of the MPI therapy by allowing cancer invasion and blood vessel formation using the “amoeboid” strategy. Even the VEGFA targeting partially disregarded the expectations because of the resistance onset followed by the progression of the disease. Our preliminary experiments showed also an “indifference” of ECs and EPCs to VEGF stimulation under amoeboid conditions. Therefore, the aim of this project is to identify the multiple mechanisms shared by cancer cells and ECs/EPCs in the regulation of amoeboid movement, to identify common therapeutic strategies impairing vascular growth and cancer cell invasion at the same time, overcoming resistance to anti-VEGF and anti-protease therapy. The molecules identified (ephrin, protease receptors, etc.) will be used as candidates for targeted therapy through the delivery of cargo liposomes containing inhibitors of the connection of such molecules with the cortical actin cytoskeleton, in pre-clinical experiments with the perspective of a possible application to humans. We expect that this approach will give a progress in the treatment of tumors thus improving outcomes for cancer patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ENDOCAM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ENDOCAM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More  

ICL CHROM (2020)

DNA interstrand crosslink repair and chromatin remodelling

Read More  

GENI (2019)

Gender, emotions and national identities: a new perspective on the abortion debates in Italy (1971-1981).

Read More